Literature DB >> 11329234

Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses.

C M Hogan1, S M Hammer.   

Abstract

The course of HIV infection varies widely among individuals. Long-term nonprogressors or slow progressors may remain asymptomatic and have normal CD4 counts despite more than a decade of untreated HIV infection. In contrast, rapid progressors develop AIDS within 5 years. In addition, some persons remain uninfected despite repeated exposure to HIV. Immunologic and genetic studies of long-term nonprogressors and exposed yet uninfected persons, as well as data from studies of primary HIV infection, have helped to elucidate the mechanisms by which some persons are protected from HIV acquisition or have slow rates of disease progression. This review (the first of two parts) describes what is currently known about host factors in HIV-1 infection. Studies for inclusion were identified by a systematic search of PubMed for English-language literature published from 1988 through June 2000. Abstracts of presentations at major meetings convened in 2000 were also included if appropriate. Growing evidence suggests a crucial role of cytotoxic T cells and T-helper cells in controlling viremia, slowing disease progression, and perhaps preventing establishment of infection. Humoral and mucosal immunity, soluble inhibitory factors, the cytokine milieu, and concomitant infections also affect outcome. Genetic host factors, such as inheritance of mutant chemokine receptors or certain HLA types, affect susceptibility to infection and subsequent clinical course. The role of cellular and humoral immunity, mucosal immunity, and other local factors in determining the course of HIV infection is discussed.

Entities:  

Mesh:

Year:  2001        PMID: 11329234     DOI: 10.7326/0003-4819-134-9_part_1-200105010-00013

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  23 in total

1.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

Review 2.  Accessing the human repertoire for broadly neutralizing HIV antibodies.

Authors:  Philip W Hammond
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

3.  Dendritic cell-mediated HIV-1 infection of T cells demonstrates a direct relationship to plasma viral RNA levels.

Authors:  Reetakshi Arora; Lara Bull; Edward B Siwak; Rajesh Thippeshappa; Roberto C Arduino; Jason T Kimata
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

4.  Alterations of natural killer cell and T-lymphocyte counts in adults infected with human immunodeficiency virus through blood and plasma sold in the past in China and in whom infection has progressed slowly over a long period.

Authors:  Yongjun Jiang; Hong Shang; Zining Zhang; Yingying Diao; Di Dai; Wenqing Geng; Min Zhang; Xiaoxu Han; Yanan Wang; Jing Liu
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

5.  CD4+ T cells from HIV-1-infected patients recognize wild-type and mutant human immunodeficiency virus-1 protease epitopes.

Authors:  N G Muller; R Alencar; L Jamal; J Hammer; J Sidney; A Sette; R M Brindeiro; J Kalil; E Cunha-Neto; S L Moraes
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

6.  Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants.

Authors:  Yuhong Jiang; Man Li; Zhirong Zhang; Tao Gong; Xun Sun
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

7.  Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy.

Authors:  Annette Oxenius; Angela R McLean; Marek Fischer; David A Price; Sarah J Dawson; Roland Hafner; Christine Schneider; Helen Joller; Bernard Hirschel; Rodney E Phillips; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 8.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

9.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.

Authors:  Sacha Gnjatic; Djordje Atanackovic; Elke Jäger; Mitsutoshi Matsuo; Annamalai Selvakumar; Nasser K Altorki; Robert G Maki; Bo Dupont; Gerd Ritter; Yao-Tseng Chen; Alexander Knuth; Lloyd J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

10.  Possession of human leucocyte antigen DQ6 alleles and the rate of CD4 T-cell decline in human immunodeficiency virus-1 infection.

Authors:  Annapurna Vyakarnam; David Sidebottom; Shahed Murad; James A Underhill; Philippa J Easterbrook; Angus G Dalgleish; Mark Peakman
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.